SEELAS Life Sciences (SLS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 - - Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML After Venetoclax Failure to be Presented at the Upcoming American Society of Hematology (ASH) Annual Meeting in December – - GPS Granted FDA Rare Pediatric Disease Designation (RPDD) f ...